pharmaceuticals

High Hopes and Expectations for Merck’s First Investor Day in Years

Merck & Co. Inc. (NYSE: MRK) may still be up in 2019, and it may be better off for now than rival Pfizer, but the reality is that Merck shares ...
Read Full Story »

Multimillion-Dollar Medical Claims Continue to Skyrocket

Whether you were in favor of or against the Affordable Care Act, aka Obamacare, it is likely of little surprise that the cost of health care has continued to rise. ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

New Sickle Cell Disease Treatment Could Be a Blockbuster With $1 Billion in Sales

Sickle cell disease impacts about 100,000 Americans, according to RethinkSCD.com. The incidence is about one in every 365 African American births and about one in every 16,300 Hispanic American births. ...
Read Full Story »

5 ASCO Winners That Could Still More Than Double

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result. Wedbush took a closer ...
Read Full Story »

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca PLC (NASDAQ: AZN) would be scaled back. AstraZeneca subsidiary MedImmune is ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

How Tonix Pharma Is Kicking Cocaine

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares jumped sharply on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication. ...
Read Full Story »

How Eli Lilly Is Making Insulin More Affordable

Drug companies have been decried in the United States for high prices, but Eli Lilly and Co. (NYSE: LLY) is looking to fight this trend — at least a little. ...
Read Full Story »

Why BioCryst’s HAE Treatment Failed to Impress

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema (HAE) patients. Specifically, the firm announced ...
Read Full Story »

Thursday’s Top 4 ASCO Movers

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago. This meeting always brings big swings in the ...
Read Full Story »

Can Danaher Walk Away From the Buyout of GE’s Biopharma Unit?

If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric Co. (NYSE: GE). A new CEO has ...
Read Full Story »

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Mylan Is Getting Absolutely Crushed

When Mylan N.V. (NASDAQ: MYL) released its first-quarter financial results before the markets opened on Tuesday, the company posted $0.82 in earnings per share (EPS) and $2.5 billion in revenue. ...
Read Full Story »